2023 World Conference on Lung Cancer (Posters)-EP06.03. Demographic and Genomic Characteristics of Non-Small Cell Lung Cancer Patients with ARID1A Alterations

EP06.03. Demographic and Genomic Characteristics of Non-Small Cell Lung Cancer Patients with ARID1A Alterations - PDF(Slides)

Back to course

Pdf Summary

This study aimed to evaluate the demographic and genomic characteristics of patients with stage IV non-small cell lung cancer (NSCLC) and alterations in the ARID1A gene, a tumor suppressor gene that plays a role in carcinogenesis. The study included 85 patients with ARID1A alterations and 184 patients without these alterations as controls.<br /><br />The results showed that patients with ARID1A alterations were more likely to be Black, younger than 65, former smokers, and have a squamous histology. They were also less likely to have EGFR co-mutations. The study found no significant differences in gender between the cases and controls.<br /><br />Molecular features analysis showed that patients with ARID1A alterations had higher PD-L1 expression and tumor mutational burden compared to the controls. ARID1A alterations were less associated with EGFR mutations and more associated with HER2 mutations. However, there were no significant differences in the frequency of other mutations such as KRAS, BRAF, MET, RET, TP53, STK11, and KEAP1.<br /><br />In terms of treatment, 67% of patients with ARID1A alterations received immune checkpoint inhibitors (ICI) as therapy, either alone or in combination with chemotherapy. The efficacy of ICI in both cases and controls is being analyzed.<br /><br />This study provides important information about the mutational landscape and demographic profile of NSCLC patients with ARID1A alterations. It supports previous findings that ARID1A alterations are associated with a lower prevalence of EGFR mutations, which has implications for the efficacy of ICI therapy. The study also suggests that ARID1A alterations may serve as a potential biomarker for predicting response to ICI therapy.<br /><br />Further analysis of the efficacy of ICI in patients with ARID1A alterations will help determine whether these alterations should be further evaluated as a biomarker for ICI efficacy.

Asset Subtitle

Ebaa Al-Obeidi

Meta Tag

Speaker Ebaa Al-Obeidi

Topic Pathology & Biomarkers: Genetic Biomarkers

Keywords

stage IV non-small cell lung cancer

NSCLC

ARID1A gene

tumor suppressor gene

carcinogenesis

demographic characteristics

genomic characteristics

EGFR co-mutations

PD-L1 expression

tumor mutational burden